Medical Xpress
New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks
A phase II clinical trial published in *Nature Medicine* found that an oral GLP-1 drug achieved up to 12% body weight reduction in overweight and obese patients over 36 weeks. The result is significant because it suggests a pill-based delivery method could rival injectable GLP-1 therapies, which have dominated the weight-loss drug market. Wider accessibility through an oral format could dramatically expand the patient population able to benefit from this class of treatment.
Read article →Medical Xpress
AI system detects sudden cardiac death risk, identifying thousands more patients annually
A new AI system can identify patients at risk of sudden cardiac death with enough precision to flag thousands of additional candidates for life-saving intervention each year. The tool addresses one of cardiology's most persistent challenges: determining who truly needs an implantable defibrillator before a fatal cardiac event strikes. With over 300,000 Americans dying annually from sudden cardiac arrest, more accurate risk stratification could have an outsized impact on survival rates.
Read article →Medical Xpress
Silk sticker is noninvasive way to monitor babies' health
Premature infants in neonatal ICUs are among medicine's most vulnerable patients, yet standard monitoring requires a web of cables and repeated blood draws that can stress skin still in development. A new silk-based adhesive sticker offers a gentler alternative, continuously tracking key health metrics without invasive procedures. The device could meaningfully reduce patient discomfort while giving clinicians real-time data on the infants who need it most.
Read article →Medical Xpress
Personalized brain imaging may improve outcomes for treatment-resistant depression
Researchers at Mass General Brigham have found that tailoring transcranial magnetic stimulation targets using personalized brain imaging significantly improves results for patients whose depression has not responded to conventional treatments. The randomized clinical trial, published in JAMA Psychiatry, marks a meaningful step forward in precision psychiatry. For the estimated 30% of depression patients who are treatment-resistant, the findings could expand access to more effective, individualized care.
Read article →Medical Xpress
Socioeconomic challenges color patients' lung cancer screening experience
Lung cancer screening via low-dose CT is broadly well tolerated, but a new study in the Journal of the American College of Radiology reveals a clear divide along socioeconomic lines. Lower-income patients and those relying on safety-net healthcare reported greater physical discomfort and emotional anxiety tied to the screening process. The findings point to systemic gaps that, if addressed, could improve both access and outcomes for the most vulnerable patients.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →